|
C20ORF4 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.3941999999999E-05 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.09710000000008E-05 |
| Normal-vs-Stage2 |
2.727800E-01 |
| Normal-vs-Stage3 |
2.09759999999504E-05 |
| Normal-vs-Stage4 |
5.65490000048463E-07 |
| Stage1-vs-Stage2 |
5.155900E-02 |
| Stage1-vs-Stage3 |
3.732400E-01 |
| Stage1-vs-Stage4 |
3.249900E-02 |
| Stage2-vs-Stage3 |
1.289910E-02 |
| Stage2-vs-Stage4 |
2.157500E-03 |
| Stage3-vs-Stage4 |
1.937610E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.37289999999168E-05 |
| Normal-vs-AfricanAmerican |
2.081600E-02 |
| Normal-vs-Asian |
3.437100E-03 |
| Caucasian-vs-AfricanAmerican |
6.309000E-01 |
| Caucasian-vs-Asian |
3.182800E-01 |
| AfricanAmerican-vs-Asian |
8.987600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.3666999999934E-05 |
| Normal-vs-Female |
5.80230000000181E-05 |
| Male-vs-Female |
6.142000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.12629999999381E-05 |
| Normal-vs-Age(41-60Yrs) |
1.193190E-04 |
| Normal-vs-Age(61-80Yrs) |
7.80710000000129E-05 |
| Normal-vs-Age(81-100Yrs) |
9.589600E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.844400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.308800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.226000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.187800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.722600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.761800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.596000E-02 |
| Classical-VS-Follicular |
8.110600E-01 |
| Classical-VS-Other |
3.577600E-01 |
| Classical-VS-Normal |
1.607870E-04 |
| Tall-VS-Follicular |
8.084300E-02 |
| Tall-VS-Other |
9.544400E-01 |
| Tall-VS-Normal |
3.96889999998429E-06 |
| Follicular-VS-Other |
5.124000E-01 |
| Follicular-VS-Normal |
1.260830E-03 |
| Other-VS-Normal |
1.237010E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.062670E-03 |
| Normal-vs-N1 |
1.22909999955567E-08 |
| N0-vs-N1 |
2.997000E-04 |
|
|
